PARCOPA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PARCOPA (PARCOPA).
Carbidopa inhibits decarboxylation of levodopa in the periphery, increasing levodopa availability to the brain. Levodopa is converted to dopamine in the CNS, replenishing dopamine levels in the striatum.
| Metabolism | Levodopa is decarboxylated to dopamine by aromatic L-amino acid decarboxylase (AAAD) peripherally; carbidopa is metabolized to alpha-methyl dopamine. Levodopa also metabolized via catechol-O-methyltransferase (COMT) to 3-O-methyldopa. |
| Excretion | Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%. |
| Half-life | Terminal elimination half-life is approximately 1.5-3 hours; in elderly patients, half-life may be prolonged due to reduced renal clearance, requiring dose adjustment. |
| Protein binding | Approximately 10-20% bound to plasma proteins, mainly albumin; low binding minimizes displacement interactions. |
| Volume of Distribution | 0.9-1.2 L/kg, indicating extensive extravascular distribution; Vd may increase with chronic use due to tissue accumulation. |
| Bioavailability | Oral bioavailability is 60-80% due to first-pass metabolism and variable absorption; controlled-release formulations have 70-80% relative bioavailability compared to immediate-release. |
| Onset of Action | Immediate-release oral: 30-60 minutes; controlled-release oral: 1-2 hours. |
| Duration of Action | Immediate-release: 4-6 hours; controlled-release: 6-12 hours; duration is dose-dependent and influenced by disease severity and concomitant medications. |
0.5 mg orally three times daily, titrated slowly based on response and tolerability; maximum 8 mg/day.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | No formal guidelines; use with caution in severe renal impairment (CrCl <30 mL/min) as drug excretion may be reduced. |
| Liver impairment | Not studied in Child-Pugh classes; avoid in severe hepatic impairment due to potential for increased exposure. |
| Pediatric use | Safety and efficacy not established; no recommended pediatric dose. |
| Geriatric use | Initiate at 0.5 mg twice daily due to increased sensitivity; titrate cautiously. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PARCOPA (PARCOPA).
| Breastfeeding | Levodopa is excreted into human milk; carbidopa is unknown. M/P ratio not established. Potential for adverse effects (e.g., growth retardation, hypotension) in nursing infant; manufacturer recommends discontinuing breastfeeding or drug due to risk. |
| Teratogenic Risk | Parcopa (carbidopa/levodopa) is assigned to Pregnancy Category C. First trimester: Risk cannot be ruled out; animal studies showed adverse effects but no adequate human studies. Second/third trimester: Limited data; avoid unless benefit outweighs risk. Levodopa may theoretically interfere with fetal dopamine development. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Concurrent use of nonselective MAO inhibitors","Narrow-angle glaucoma","History of malignant melanoma or suspicious undiagnosed skin lesions","Known hypersensitivity to any component"]
| Precautions | ["May cause falling asleep during activities of daily living","May cause hallucinations or psychosis","May cause impulse control disorders","May cause dyskinesias","Risk of melanoma","May cause neuroleptic malignant syndrome on abrupt withdrawal","May cause orthostatic hypotension","May cause hemolytic anemia in G6PD deficiency","May cause gastrointestinal bleeding"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, motor function, and signs of dyskinesia or psychiatric symptoms. Fetal assessment via ultrasound to detect growth abnormalities if exposure occurs in late pregnancy. |
| Fertility Effects | No human data. Animal studies show no significant fertility impairment with carbidopa/levodopa. |